Vymada and Entresto are the same active-drug combination (sacubitril/valsartan) but different brand names and same manufacturer-Norvatis; their clinical effects, approved indication (heart failure with reduced ejection fraction), mechanism (angiotensin receptor–neprilysin inhibitor), and core safety profile are the same, while differences are limited to manufacturer, country approvals, pricing, and product labeling.
Where Vymada and Entresto Differ
- Different Brands same manufacturer — Entresto is the original Novartis brand for sacubitril/valsartan; Vymada is a different branded/generic product name of the same combination produced by the same manufacturer- Norvatis.
- Regulatory status and labeling — Entresto’s product information and EMA/FDA regulatory documents outline approved indications, dosing, contraindications, and pharmacovigilance specific to that marketed product; other brands will have their own local approvals and labels which may differ slightly in presentation or approved country-specific indications.
- Pricing and availability — generic/branded alternatives (like Vymada in some markets) can differ substantially in price and local availability compared with Entresto; market availability depends on national approvals and patents.
- Packaging, excipients, and formulation details — non-active ingredients, tablet appearance, and packaging will vary by manufacturer; these differences do not change the active pharmacology but can matter for allergies or patient preference.
What Vymada and Entresto share
- Active ingredients and class — both contain sacubitril plus valsartan and are an angiotensin receptor–neprilysin inhibitor (ARNI).
- Main indication — both are used for symptomatic chronic heart failure with reduced ejection fraction (HFrEF) to reduce cardiovascular death and heart-failure hospitalisations.ema.europa+1
- Evidence base — the clinical benefit shown in pivotal trials (for sacubitril/valsartan vs enalapril) applies to the molecule regardless of brand; guideline and regulator assessments reference this evidence for the active combination.ema.
Safety, dosing, and switching notes
- Safety profile and major warnings (contraindicated with ACE inhibitors without appropriate washout because of angioedema risk, pregnancy risk, hypotension, renal function monitoring, hyperkalemia risk) stem from the sacubitril/valsartan molecule and apply to both brands; always follow the specific product label and local guidance.
- Dosing principles (start, titrate to target dose when tolerated, observe 36-hour washout if switching from ACE inhibitor) are the same across brands because they reflect the active drug’s pharmacology and trial protocols.
Practical recommendation for prescribers and patients
- If you are prescribed either product, confirm the active ingredients (sacubitril/valsartan), check the local product label for approved dosing and warnings, and follow your clinician’s guidance on switching, dosing titration, and monitoring.
- If cost or availability is the concern, discuss branded Entresto versus locally available alternatives (like Vymada) with your prescriber or pharmacist — generics/other brands may be more affordable but ensure they are from reputable manufacturers and approved by local regulators.